25HC3S Cyclodextrin Compositions for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug formulations for 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) face challenges in achieving high efficacy, low toxicity, storage stability, high solubility, and isotonicity, making it difficult to predict the most appropriate formulation strategy for new drug compounds.
Innovation Solution
Compositions comprising 25HC3S or pharmaceutically acceptable salt thereof, combined with cyclic oligosaccharides such as cyclodextrins and propylene glycol, are developed to enhance solubility, stability, and safety, allowing for formulations suitable for various administration routes including oral, topical, and injectable forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug formulations are used for 25HC3S, then the drug can be administered, but achieving high efficacy, low toxicity, storage stability, high solubility, and isotonicity simultaneously is difficult
Solution Approach 1:
The patent employs composite formulation strategies by combining 25HC3S with cyclodextrin derivatives and other excipients in specific ratios to achieve multiple therapeutic goals simultaneously. This composite approach allows the formulation to deliver high efficacy while maintaining stability, solubility, and isotonicity properties that cannot be achieved with single-component formulations.
Solution Approach 2:
The patent systematically adjusts formulation parameters including concentration levels, pH, osmolality, and temperature to optimize the therapeutic profile. By changing these parameters within specific ranges, the formulation achieves high efficacy while maintaining low toxicity and stable storage characteristics.
2Reliability
If formulation strategies are optimized for high efficacy, then therapeutic effect is improved, but predicting the most appropriate strategy ab initio becomes difficult
Solution Approach 1:
The patent develops a universal formulation framework that can be applied across different therapeutic indications for 25HC3S. The formulation system is designed to be multi-functional, achieving efficacy, stability, solubility, and isotonicity simultaneously through a standardized approach that simplifies development across different applications.
3Quantity of substance
If cyclodextrin derivatives are used to enhance solubility, then solubility is improved, but formulation complexity increases
Solution Approach 1:
The patent uses cyclodextrin derivatives as intermediary substances that facilitate the solubility enhancement of 25HC3S. These intermediaries form inclusion complexes with the drug compound, improving solubility while the structured nature of cyclodextrin derivatives provides predictable formulation behavior that manages complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively prevent and treat a wide range of diseases and conditions, including acute liver failure, hyperlipidemia, inflammatory diseases, and organ failure, with improved solubility, stability, and reduced toxicity.
Implementation Method 1
Compositions comprising 25HC3S or pharmaceutically acceptable salt thereof, combined with cyclic oligosaccharides such as cyclodextrins
Implementation Method 2
Compositions comprising 25HC3S or pharmaceutically acceptable salt thereof, combined with cyclic oligosaccharides such as cyclodextrins and propylene glycol
Data Source
AI summary
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.